GSK to invest up to $110 million in expanded AI drug-discovery partnership with Relation Therapeutics

GSK announced it will pay Relation Therapeutics up to $110 million to broaden their existing collaboration that uses artificial‑intelligence models to identify new drug candidates.

The expanded agreement will see Relation apply its AI platform to additional therapeutic areas, building on earlier work that aimed to improve success rates in early‑stage discovery.

GSK expects the deeper use of AI to accelerate target identification and reduce the time and cost of bringing compounds into development, though specific timelines were not disclosed.

The deal reflects growing interest in computational approaches across the pharma industry as companies seek to enhance their pipelines.